• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

语言能力与生物制剂可及性:美国银屑病患者的一项人群研究。

Language proficiency and biologics access: a population study of psoriasis patients in the United States.

作者信息

Chat Vipawee S, Hekmatjah Joshua, Sierro Tiffany J, Kassardjian Ari A, Read Charlotte, Armstrong April W

机构信息

Medical College of Georgia, Augusta University, Augusta, GA, USA.

Homer Stryker M.D. Schoolof Medicine, Western Michigan University, Kalamazoo, MI, USA.

出版信息

J Dermatolog Treat. 2022 May;33(3):1413-1417. doi: 10.1080/09546634.2020.1820936. Epub 2020 Sep 14.

DOI:10.1080/09546634.2020.1820936
PMID:32928008
Abstract

BACKGROUND

Language proficiency plays an important role in healthcare choices and access. Differences in access to biologic medications exist, but it is unknown how much English proficiency influences access in US psoriasis patients.

OBJECTIVE

To compare biologic medication use for psoriasis patients with differing English proficiency levels.

METHODS

Population study of US psoriasis patients using the 2013-2017 Medical Expenditure Survey.

RESULTS

Among a total of 4,470,820 US psoriasis patients (weighted), 4,028,119 (90.1%) had perfect English proficiency, and 442,700 (9.9%) had less than perfect English proficiency. Among the total population, 422,523 (9.5%) had access to biologics. Among those who received biologics, 411,411 (97.4%) of those had perfect English proficiency, and 11,112 (2.6%) of those had less than perfect English proficiency. Multivariate logistic regression found that patients with less than perfect English proficiency were significantly less likely to have access to biologics [OR 0.015 (95% CI: 0.001-0.179);  = .002], after adjusting for insurance status, income, education, healthcare utilization, and other sociodemographic and clinical factors.

LIMITATIONS

Psoriasis disease severity not specified.

CONCLUSIONS

Psoriasis patients with low English proficiency are significantly less likely to receive biologics than those with high English proficiency. Those with higher English proficiency are 61 times more likely to access biologics.

摘要

背景

语言能力在医疗保健选择和可及性方面起着重要作用。生物药物的可及性存在差异,但尚不清楚英语水平对美国银屑病患者获得药物治疗的影响程度。

目的

比较不同英语水平的银屑病患者使用生物药物的情况。

方法

利用2013 - 2017年医疗支出调查对美国银屑病患者进行人群研究。

结果

在总计4470820名美国银屑病患者(加权)中,4028119名(90.1%)英语水平极佳,442700名(9.9%)英语水平欠佳。在总人群中,422523名(9.5%)能够使用生物制剂。在使用生物制剂的患者中,411411名(97.4%)英语水平极佳,11112名(2.6%)英语水平欠佳。多因素逻辑回归分析发现,在调整保险状况、收入、教育程度、医疗保健利用率以及其他社会人口统计学和临床因素后,英语水平欠佳的患者获得生物制剂治疗机会的可能性显著降低[比值比0.015(95%可信区间:0.001 - 0.179);P = 0.002]。

局限性

未明确银屑病疾病严重程度。

结论

英语水平低的银屑病患者比英语水平高的患者获得生物制剂治疗的可能性显著更低。英语水平较高的患者获得生物制剂治疗的可能性高出61倍。

相似文献

1
Language proficiency and biologics access: a population study of psoriasis patients in the United States.语言能力与生物制剂可及性:美国银屑病患者的一项人群研究。
J Dermatolog Treat. 2022 May;33(3):1413-1417. doi: 10.1080/09546634.2020.1820936. Epub 2020 Sep 14.
2
No Racial Differences Found in Access to Biologics: A Population-Based Study of Psoriasis Patients in the United States.未发现生物制剂获取方面的种族差异:美国银屑病患者的一项基于人群的研究。
J Drugs Dermatol. 2023 Aug 1;22(8):835-837. doi: 10.36849/jdd.7134.
3
Disparities in Health Insurance Coverage and Access to Care by English Language Proficiency in the USA, 2006-2016.2006 - 2016年美国按英语语言能力划分的医疗保险覆盖范围和医疗服务可及性差异
J Gen Intern Med. 2020 May;35(5):1490-1497. doi: 10.1007/s11606-019-05609-z. Epub 2020 Jan 2.
4
Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.初治生物制剂的银屑病患者开始使用阿普米司特或生物制剂的真实世界治疗模式及医疗费用
J Med Econ. 2019 Apr;22(4):365-371. doi: 10.1080/13696998.2019.1571500. Epub 2019 Feb 4.
5
Where you live matters: Regional differences in health care resource use for psoriasis in the United States.居住地很重要:美国银屑病医疗资源使用的地区差异。
J Am Acad Dermatol. 2020 Jun;82(6):1360-1367. doi: 10.1016/j.jaad.2019.10.014. Epub 2019 Oct 10.
6
Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.接受生物制剂治疗的银屑病患者的医疗资源利用情况及费用,总体情况及按疾病严重程度划分的情况。
J Med Econ. 2018 Aug;21(8):745-754. doi: 10.1080/13696998.2018.1472097. Epub 2018 May 22.
7
Rethinking costs of psoriasis: 10% of patients account for nearly 40% of healthcare expenditures among enrollees with psoriasis in a U.S. health plan.重新审视银屑病的成本:在美国一项医保计划中,10%的银屑病患者占了银屑病参保者近40%的医疗支出。
J Dermatolog Treat. 2017 Nov;28(7):613-622. doi: 10.1080/09546634.2017.1303566. Epub 2017 Mar 20.
8
Equity in the usage of biologics for psoriasis in the working poor.在贫困劳动者中使用生物制剂治疗银屑病的公平性。
Arch Dermatol Res. 2023 May;315(4):1029-1031. doi: 10.1007/s00403-022-02410-7. Epub 2022 Oct 28.
9
Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.美国中重度银屑病成人患者的真实世界健康结局:一项利用电子健康记录进行的人群研究,以考察患者感知的治疗效果、药物使用及医疗资源利用情况。
BMC Dermatol. 2018 Jun 28;18(1):4. doi: 10.1186/s12895-018-0072-2.
10
Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.美国患有风湿性疾病或银屑病的退伍军人的治疗模式和年度生物制剂成本。
J Med Econ. 2016;19(1):34-43. doi: 10.3111/13696998.2015.1086774. Epub 2015 Sep 30.